Achieving A1C targets is a fundamental component of quality measures such as HEDIS and Star ratings. A typical basal-bolus insulin regimen requires 4 insulin injections a day. Adherence decreases as the number of injections increases and non-adherence to therapy is a primary reason for failure to achieve glycemic control. Less invasive options for insulin delivery may improve patient adherence leading to positive clinical outcomes. This multi-state retrospective analysis evaluated the achievement of glycemic targets compared to prior therapy in 186 patients switched from a basal-bolus regimen to a 24-hour wearable insulin delivery device (V-Go). At baseline, mean A1C was 9.1%, weight 219 lbs and insulin total daily dose (TDD) was 84 u/day across a mean of 4.3 injections/day. Forty-five percent of patients were poorly controlled (A1C > 9%) and less than 30% had achieved an A1C < 8% despite basal-bolus therapy. After 7 months of V-Go use, changes from baseline in A1C and TDD were significant (P<0.0001). Mean change (95% CI) in A1C was -1.02% (-1.24, -0.78) and TDD was reduced by 32% or 25 u/day (31, 19). Weight did not significantly change. Switching to V-Go, resulted in significant improvement to achievement of glycemic targets (90% increase in A1C values < 8% and 50% decrease in A1C values > 9%) compared to prior basal-bolus regimen, having positive implications on quality metrics.


R.S. Hundal: Speaker's Bureau; Self; Valeritas, Inc., Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca, Novo Nordisk Inc., Amarin Corporation, Eli Lilly and Company, Merck & Co., Inc. S. Kowalyk: Speaker's Bureau; Self; Valeritas, Inc.. J. Cases: None. A. Al-Karadsheh: None. A.P. Wakim: Speaker's Bureau; Self; Versartis, Inc.. Research Support; Self; Valeritas, Inc.. M. Doyle: None. J.H. Sink: Other Relationship; Self; Janssen Pharmaceuticals, Inc., valeritas. Speaker's Bureau; Self; Novo Nordisk Inc.. Consultant; Self; Becton, Dickinson and Company. A. Spence: None. J.L. Brewer: Speaker's Bureau; Self; Valeritas, Inc., Janssen Pharmaceuticals, Inc. C.C. Nikkel: Employee; Self; Valeritas, Inc.. Stock/Shareholder; Self; Valeritas, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at